Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granules
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infections, Human Immunodeficiency Virus and Herpesviridae
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Trial Timeline
Jun 1, 2011 → Aug 1, 2011
NCT ID
NCT01382238About Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granules
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granules is a phase 1 stage product being developed by Shionogi for Infections, Human Immunodeficiency Virus and Herpesviridae. The current trial status is completed. This product is registered under clinical trial identifier NCT01382238. Target conditions include Infections, Human Immunodeficiency Virus and Herpesviridae.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01382238 | Phase 1 | Completed |
Competing Products
20 competing products in Infections, Human Immunodeficiency Virus and Herpesviridae